- HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
- Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
- HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
- HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
- HeartSciences Regains Compliance with Nasdaq Listing Requirements
- HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
- HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
- HeartSciences to Present at the LD Micro Invitational XIV Conference
- HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
More ▼
Key statistics
On Monday, Heart Test Laboratories Inc (HSCS:NAQ) closed at 4.11, 20.88% above the 52 week low of 3.40 set on Jul 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.42 |
---|---|
High | 4.80 |
Low | 4.10 |
Bid | -- |
Offer | -- |
Previous close | 4.11 |
Average volume | 56.46k |
---|---|
Shares outstanding | 655.62k |
Free float | 550.66k |
P/E (TTM) | -- |
Market cap | 2.69m USD |
EPS (TTM) | -0.4912 USD |
Data delayed at least 15 minutes, as of Jul 29 2024 21:00 BST.
More ▼